Form 8-K - Current report:
SEC Accession No. 0001193125-25-045673
Filing Date
2025-03-04
Accepted
2025-03-04 16:47:03
Documents
15
Period of Report
2025-03-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d924521d8k.htm   iXBRL 8-K 26326
2 EX-99.1 d924521dex991.htm EX-99.1 30247
6 GRAPHIC g924521page005.jpg GRAPHIC 5625
  Complete submission text file 0001193125-25-045673.txt   195286

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA iobt-20250304.xsd EX-101.SCH 2855
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE iobt-20250304_lab.xml EX-101.LAB 17909
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE iobt-20250304_pre.xml EX-101.PRE 11237
17 EXTRACTED XBRL INSTANCE DOCUMENT d924521d8k_htm.xml XML 3616
Mailing Address OLE MAALOES VEH 3 COPENHAGEN G7 2200
Business Address OLE MAALOES VEH 3 COPENHAGEN G7 2200 4570702980
IO Biotech, Inc. (Filer) CIK: 0001865494 (see all company filings)

EIN.: 870909276 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41008 | Film No.: 25705594
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)